STATEMENT: After Years Of Advocacy, Patients Will See Long-Awaited Relief From Eli Lilly’s Insulin Price Cut
“It’s Time For The Other Big Insulin Corporations To Follow Suit”
ICYMI: Q&A With P4AD’s Executive Director Merith Basey
Patient Advocate Lisa Ann Wetzel-Trainor Moderated A Conversation Where Merith Answered Questions On Her Background, The Inflation Reduction Act, And P4AD’s Future Goals:
STATEMENT: Unjustified Price Of New ALS Treatment Reinforces Fact That Our Drug Pricing System Fails The People It Is Supposed To Serve – Patients
The following statement was issued by David Mitchell, a cancer patient and founder and president of Patients For Affordable Drugs, in response to the pricing of Relyvrio following the Food and Drug Administration’s approval of the drug combination to treat amyotrophic lateral sclerosis (ALS):
Merith Basey Named Executive Director Of Patients For Affordable Drugs
Basey Has Devoted Her Career To Ensuring That Life-saving Medications Are Affordable And Accessible For All Who Need Them
JULY PRICE HIKES REPORT: Big Pharma’s Continued Greed Underscores Urgent Need For Reform To Lower Drug Prices
In The Third Year Of The Pandemic And As Americans Grapple With Record Inflation, Big Pharma Continues To Raise Prices And Exploit Patients
NEW REPORT: Big Pharma’s Lockstep Price Hikes On Widely Used Blood Thinners Exploit Patients And Taxpayers
A new report issued today documents how drug companies use their market and political power to avoid competition and raise prices in lockstep.
JANUARY PRICE HIKES 2.0: Big Pharma Pushes Blockbuster Prices To New Heights
Since P4AD’s initial report in mid-January, drug companies have increased the price of 188 more drugs, bringing the total to 742 hikes so far this year.
JANUARY 2022 PRICE HIKES REPORT: A New Year Brings The Same Old Bad Behavior By Big Pharma
The report demonstrates why urgent congressional action is needed to address Big Pharma’s abusive pricing practices.
